FAQ

Darunavir:Susc:Pt:Isolate:OrdQn:Phenotyping

Known as: Darunavir:Susc:Pt:Isolato:OrdQn:Fenotipizzazione, Darunavir:Susceptibility:Point in time:Isolate:Quantitative or Ordinal:Phenotyping, Darunaviir:Susc:Pt:Is:OrdQn:Fenotüpiseerimine 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2016
0120082016

Related topics

Related topics

3 relations
Isolate - microorganismPhenotype determinationdarunavir

Related mentions per year

Related mentions per year

1938-2018
19401960198020002020
Darunavir:Susc:Pt:Isolate:OrdQn:Phenotyping
Phenotype determination
darunavir
Isolate - microorganism

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies.
BACKGROUND Darunavir 800 mg once daily (QD) is indicated for HIV-1-infected treatment-naïve and treatment-experienced (without… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2016
2016
In-vivo bioavailability and lymphatic uptake evaluation of lipid nanoparticulates of darunavir.
Darunavir is effective against wild-type and PI-resistant HIV, and has an oral bioavailability of 37%. It needs to be combined… (More)
Is this relevant?
2014
2014
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial
BACKGROUND Cobicistat is an alternative pharmacoenhancer to ritonavir. In healthy volunteers, darunavir exposure was comparable… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2009
2009
Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC.
AIMS ABCB1, some ABCCs and SLCOs have been reported to affect the intracellular accumulation of various protease inhibitors in… (More)
  • figure 1
  • figure 2
Is this relevant?
2008
2008
Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.
Data from two Phase IIb trials, POWER 1 and 2 (TMC114-C213 and C202), were pooled to examine the effect of baseline viral… (More)
Is this relevant?